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1845Low-Flow, Low-Gradient Aortic Stenosis in
Normal and Depressed Left Ventricular Ejection FractionPhilippe Pibarot, Jean G. Dumesnil
Low-flow, low-gradient aortic stenosis (AS) may occur with depressed or preserved left
ventricular ejection fraction (LVEF). In both cases, the decrease in gradient relative to AS
severity is due to a reduction in transvalvular flow. The main challenge in patients with
depressed LVEF is distinguishing between true-severe and pseudo-severe stenosis, and
dobutamine echocardiography is the preferred strategy. Paradoxical low-flow, low-gradient
severe AS despite a normal LVEF is a recently described entity, which is characterized by
pronounced LV concentric remodeling and a restrictive physiology that is often misdiagnosed
and leads to inappropriate delays for surgery. Pibarot and Dumesnil review the diagnostic and
therapeutic management of low-flow, low-gradient AS with and without depressed LV
function.STATE-OF-THE-ART PAPERS1854Calcific Aortic Stenosis: A Disease of the Valve and the MyocardiumMarc R. Dweck, Nicholas A. Boon, David E. Newby
Although aortic stenosis (AS) is a common condition associated with major morbidity,
mortality and economic costs, there are currently no medical interventions capable of delaying
or halting its progression. Dweck and colleagues review the pathophysiology of AS, which is
characterized by progressive aortic valve narrowing and secondary left ventricular hypertrophy,
emphasizing that both processes contribute to the symptoms and adverse events of AS. The
roles of inflammation, fibrosis, and calcification are discussed, as is the development of left
ventricular hypertrophy, its subsequent decompensation, and the transition to heart failure.
Potential therapeutic strategies including statins, angiotensin-converting enzyme inhibitors,
and bisphosphonates are reviewed, though evidence of their clinical efficacy is lacking.(continued on page A-24)
NOVEMBER 6, 2012 (continued) A-24CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY1864Long-Term Outcomes Following Transcatheter Aortic Valve ImplantationJosep Rodés-Cabau, John G. Webb, Anson Cheung, Jian Ye, Eric Dumont, Mark Osten, Chris Feindel,
Madhu K. Natarajan, James L. Velianou, Giussepe Martucci, Benoît DeVarennes, Robert Chisholm,
Mark Peterson, Christopher R. Thompson, David Wood, Stefan Toggweiler, Ronen Gurvitch,
Samuel V. Lichtenstein, Daniel Doyle, Robert DeLarochellière, Kevin Teoh, Victor Chu, Kevin Bainey,
Kevin Lachapelle, Asim Cheema, David Latter, Jean G. Dumesnil, Philippe Pibarot, Eric Horlick
Rodés-Cabau and colleagues evaluated the long-term outcomes following transcatheter aortic
valve implantation (TAVI) focusing on valve durability and the causes and predictors of late
mortality. This was a multicenter study including 339 patients considered to be nonoperable
or at very high surgical risk who underwent TAVI with a balloon-expandable Edwards valve
(Edwards Lifesciences, Inc., Irvine, California). At a mean follow-up of 42 months, 56% had
died: 59% from known noncardiac causes, 23% from known cardiac etiology. The predictors
of late mortality were chronic obstructive pulmonary disease, chronic kidney disease, chronic
atrial fibrillation, and frailty. There were no cases of structural valve failure. These results
show a 3-year mortality rate after TAVI, but the device itself appears durable, with most
deaths of a noncardiac etiology.CORONARY ARTERY DISEASE1876Appropriateness of Coronary Revascularization ProceduresDennis T. Ko, Helen Guo, Harindra C. Wijeysundera, Madhu K. Natarajan, A. Dave Nagpal,
Christopher M. Feindel, Kori Kingsbury, Eric A. Cohen, Jack V. Tu, for the Cardiac Care Network (CCN)
of Ontario Variations in Revascularization Practice in Ontario (VRPO) Working Group
Ko and colleagues assessed the appropriateness of coronary revascularization and its
association with long-term outcomes. A population-based cohort of stable patients
undergoing cardiac catheterization was assembled, including 1,625 patients. The
appropriateness for coronary revascularization was retrospectively adjudicated. Percutaneous
coronary intervention or coronary artery bypass grafting was only performed in 69% of
patients who had an appropriate indication for coronary revascularization. In these appropriate
patients, coronary revascularization was associated with a lower adjusted hazard of death or
acute coronary syndrome (hazard ratio: 0.61) at 3 years compared with medical therapy.
There was no difference in outcomes for revascularized patients with uncertain or
inappropriate indications. These results show both substantial underutilization and
overutilization of coronary revascularization.
Editorial Comment: Manesh R. Patel, p. 1885(continued on page A-25)
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eCARDIOMETABOLIC RISK1888AMG 145 Effects on LDL-C, Safety, and TolerabilityClapton S. Dias, Adam J. Shaywitz, Scott M. Wasserman, Brian P. Smith, Bing Gao, Dina S. Stolman,
Caroline P. Crispino, Karen V. Smirnakis, Maurice G. Emery, Alexander Colbert, John P. Gibbs,
Marc W. Retter, Blaire Cooke, Stephen T. Uy, Mark Matson, Evan A. Stein
Proprotein convertase subtilisin/kexin type 9 (PCSK9) down-regulates surface expression of
the low-density lipoprotein receptor (LDL-R), increasing serum low-density lipoprotein
cholesterol (LDL-C). Dias and colleagues report the results of a series of experiments with
AMG 145, a fully human monoclonal antibody to PCSK9. In a phase 1a trial, healthy adults
received varying doses; phase 1b trials involved hypercholesterolemic subjects, subjects on
high-dose statins, and subjects with heterozygous familial hypercholesterolemia. AMG 145
reduced LDL-C up to 64% versus placebo after 1 dose and up to 81% with repeated doses.
No serious adverse events (AEs) occurred, and the rates of treatment-emergent adverse events
were similar between AMG145 and placebo. This study confirms that hypothesis that
disrupting the interaction between PCSK9 and LDL-Rs can lower serum LDL levels.HEART FAILURE
1899Correlations Between Exercise Volume and
Clinical Outcomes in Patients With Heart FailureSteven J. Keteyian, Eric S. Leifer, Nancy Houston-Miller, William E. Kraus, Clinton A. Brawner,
Christopher M. O’Connor, David J. Whellan, Lawton S. Cooper, Jerome L. Fleg, Dalane W. Kitzman,
Alain Cohen-Solal, James A. Blumenthal, David S. Rendall, Ileana L. Pinã, for the HF-ACTION Investigators
The HF-ACTION trial showed that among patients with heart failure (HF), regular exercise
reduces the risk for all-cause mortality or hospitalization. Keteyian and colleagues reviewed
the data to determine whether greater volumes of exercise correlated with greater reductions
in clinical events. Almost 1,000 subjects randomized to the exercise training arm of
HF-ACTION were followed for a median of 28 months. For the endpoint of cardiovascular
mortality or HF hospitalization, exercise volume was a significant linear and logarithmic
predictor. Moderate exercise volumes of 3 to 5 and 5 to 7 MET-h per week were
ssociated with reductions in subsequent risk that exceeded 30%. These results confirm that
ven moderate levels (3 to 7 MET-h per week) of exercise result in a clinical benefit.(continued on page A-26)
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1906Poor Outcomes Following Continuous Ultrafiltration Therapy
in Patients With Refractory ADHFMaria Patarroyo, Edgard Wehbe, Mazen Hanna, David O. Taylor, Randall C. Starling, Sevag Demirjian,
W. H. Wilson Tang
Patarroyo and colleagues reviewed their data from 63 consecutive adult patients with acute
decompensated heart failure (ADHF) who required slow continuous ultrafiltration (SCUF)
due to congestion refractory to hemodynamically-guided intensive medical therapy. After
48 h of SCUF, there were significant improvements in hemodynamic variables including
central venous pressure, pulmonary wedge pressure, and cardiac index. However, there were no
significant improvements in serum creatinine, and 59% required conversion to continuous
hemodialysis during their hospital course. A total of 14% were dialysis-dependent at hospital
discharge, 30% died during hospitalization, and a further 10% were discharged to hospice care. In
this single center experience, SCUF for refractory ADHF was associated with high incidence
permanent renal damage and mortality despite significant improvement in hemodynamics.
Editorial Comment: Larry A. Weinrauch, Akshay S. Desai, Eldrin F. Lewis, John A. D’Elia,
p. 1913HEART FAILURE1916Quantitative Expression of the Mutated Lamin A/C GeneNupoor Narula, Valentina Favalli, Paolo Tarantino, Maurizia Grasso, Andrea Pilotto, Riccardo Bellazzi,
Alessandra Serio, Fabiana I. Gambarin, Philippe Charron, Benjamin Meder, Yigal Pinto, Perry M. Elliott,
Jens Mogensen, Martino Bolognesi, Michela Bollati, Eloisa Arbustini
Lamin A/C (LMNA) mutations occur in approximately 8% of familial cases of dilated
ardiomyopathy (DCM). Narula and colleagues studied quantitative gene expression (QGE) of
he LMNA gene in blood and myocardium. QGE of LMNA was compared between affect
LMNA mutation carriers, unaffected carriers, patients with DMC not related to LMNA
mutations, and healthy controls. Subjects with LMNA mutations have lower expression of the
mutated gene in mRNA in peripheral blood as well as the myocardium compared to both normal
controls and DCM patients with wild-type LMNA. The authors propose that peripheral blood
QGE may be a less expensive screening test for identifying LMNA mutations carriers.HEART RHYTHM DISORDERS19215- Year Outcomes for Catheter Ablation of LS-AFRoland Richard Tilz, Andreas Rillig, Anna-Maria Thum, Anita Arya, Peter Wohlmuth, Andreas Metzner,
Shibu Mathew, Yasuhiro Yoshiga, Erik Wissner, Karl-Heinz Kuck, Feifan Ouyang
This study describes the 5-year efficacy of catheter ablation for longstanding-persistent atrial
fibrillation (LS-AF). A total of 202 patients underwent a sequential ablation strategy for
symptomatic LS-AF. Initial ablation strategy was circumferential pulmonary vein isolation
(PVI). Additional ablation was only performed in acute PVI nonresponder. After the first ablation
procedure sinus rhythm (SR) was documented in 20% of patients. Following multiple procedures,
SR was maintained in 45%. In the 50% of patients who were acute responders to PVI, one-half
remained in SR with no further procedures at long-term follow-up.Editorial Comment: J. David Burkhardt, Luigi Di Biase, Andrea Natale, p. 1930
(continued on page A-27)
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Joris R. de Groot, Antonie J. H. H. M. van Oostrom, Dominic A. M. J. Theuns, Luc J. L. M. Jordaens,
Arthur A. M. Wilde, Reinoud E. Knops
A new entirely subcutaneous implantable cardioverter-defibrillator (S-ICD has been introduced;
no placement of leads in or on the heart is required. Olde Nordkamp and colleagues report their
experience with the first 118 Dutch patients implanted with this device. After 18 months of
follow-up, 8 patients experienced 45 successful appropriate shocks (98% first shock conversion
efficacy). No sudden deaths occurred. A total of 13% received inappropriate shocks, mainly due
to T-wave oversensing, which was mostly solved by a software upgrade and changing the
sensing vector. A total of 14% experienced complications, with higher rate during the first 15
implantations per centre. This study demonstrates that the S-ICD is effective in terminating
ventricular arrhythmias, but does have a substantial learning curve for implanting physicians.CARDIAC RESYNCHRONIZATION
1940CRT Improves Quality of Life in Patients
With Minimally Symptomatic Heart FailurePeter J. Veazie, Katia Noyes, Qinghua Li, W. Jackson Hall, April Buttaccio, Kelly Thevenet-Morrison,
Arthur J. Moss
This study compared the quality of life (QOL) of patients implanted with a cardiac-
resynchronization therapy implantable cardioverter-defibrillator (CRT-ICD) to patients with an
ICD only using data from the MADIT-CRT trial. These 1,820 subjects had ischemic
cardiomyopathy (New York Heart Association [NYHA] functional class I or II) or nonischemic
cardiomyopathy (NYHA functional class II only), sinus rhythm, an ejection fraction of 30% or
less, and a QRS duration of 130 ms or more. During follow-up, the CRT-ICD group had greater
improvement on all Kansas City Cardiomyopathy Questionnaire measures. These differences were
significant among patients with left bundle branch block (LBBB), but not in those without
LBBB. These results extend previous data showing improved mortality with CRT in appropriate
patients to include improvements in QOL.HEART VALVE DISEASE1945Role of Circulating Osteogenic Progenitor Cells in Calcific Aortic StenosisMario Gössl, Sundeep Khosla, Xin Zhang, Nara Higano, Kyra L. Jordan, Darrell Loeffler, Maurice Sarano,
Ryan J. Lennon, Lilach O. Lerman, Amir Lerman
Recent evidence suggests that rather than passive mineralization, aortic valve calcification
(AVC) is an active osteoblastic process. Gössl and colleagues have recently identified
circulating endothelial progenitor cells (EPC) with osteogenic properties (EPC-OCN).
Using flow cytometry of peripheral blood, patients with severe aortic stenosis (AS) showed
significantly higher numbers of EPC-OCN than controls, and a higher percentage of EPC
co-stained for OCN. A similar pattern was found in young patients with biscuspid aortic
valves. CD34/OCN cells were abundant in the endothelial and deeper cell layers of
calcific but not normal aortic valve tissue, further suggesting a pathological role.Editorial Comment: Emile R. Mohler III, Frederick S. Kaplan, Robert J. Pignolo, p. 1954
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1956Impressive Effects of RD on Arterial Stiffness and
Central Hemodynamics in Patients With Resistant Hypertension Baseline 
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Brandt and colleagues investigated the effect of catheter-based renal sympathetic denervation (RD)
on central hemodynamics in patients with resistant hypertension. A total of 110 patients
underwent bilateral RD. Radial artery applanation tonometry and pulse wave analysis were used to
derive central aortic pressure and hemodynamic indices at baseline, 1, 3, and 6 months after
ablation. RD significantly reduced mean central aortic blood pressure by approximately 20 mm Hg
with results sustained at 6 months. Aortic pulse pressure, aortic augmentation and augmentation
index, carotid to femoral pulse wave velocity, ejection duration, and aortic systolic pressure load
were all lower at 6 months. This study confirms that RD, in addition to its effects on brachial
blood pressure, significantly improves arterial stiffness and central hemodynamics.CONGENITAL HEART DISEASE
1966Staged LV Recruitment Following Single Ventricle Palliation
in Patients With Borderline Left Heart HypoplasiaSitaram M. Emani, Doff B. McElhinney, Wayne Tworetzky, Patrick O. Myers, Brian Schroeder,
David Zurakowski, Frank A. Pigula, Gerald R. Marx, James E. Lock, Pedro J. del Nido
In an attempt to stimulate growth of the left ventricle (LV) and the possibility of eventual
biventricular circulation in patients with left heart hypoplasia, Emani and colleagues have
applied a strategy in which the circulation is initially supported with single ventricle palliation
while staged procedures are employed to promote blood flow through the LV. These
procedures include relieving inflow and outflow tract obstructions, resecting endocardial
fibroelastosis, and partial closure of the atrial septal defect. This report documents the
strategies employed and outcomes of 34 patients who underwent this “staged LV
recruitment.” Most patients undergoing staged LV recruitment demonstrated gradual
improvement in LV ejection fraction and dimensions, such that one-third of the patients
were eventually successfully converted to a biventricular circulation.EXPEDITED PUBLICATION1975Novel Covered Stent May Reduce Distal Thrombosis in STEMI PatientsGregg W. Stone, Alexandre Abizaid, Sigmund Silber, Jose M. Dizon, Béla Merkely, Ricardo A. Costa,
Ran Kornowski, Andrea Abizaid, Roman Wojdyla, Akiko Maehara, Ovidiu Dressler, Sorin J. Brener,
Eli Bar, Dariusz Dudek
The MGuard (InspireMD, Tel Aviv, Israel) is a novel thin-strut metallic stent with a novel poly-
ethylene terephthalate (PET) micronet covering designed to trap and exclude thrombus and friable
atheromatous debris to prevent distal embolization. Stone and colleagues performed a randomized,
multicenter trial in 433 patients with acute ST-segment elevation myocardial infarction (STEMI).
The primary endpoint of post-procedure complete ST-segment resolution (STR) measured 60 to
90 min post-procedure was significantly improved in patients randomized to the MGuard stent
compared to control. The MGuard stent also resulted in superior rates of TIMI flow grade 3,
with no differences in mortality or major adverse cardiac events at 30 days. A larger randomized
trial appears warranted to determine whether the MGuard covered stent results in reduced infarct
size and/or improved clinical outcomes in STEMI patients.
